IFRX - InflaRx N.V.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
3.4000
-0.0900 (-2.58%)
At close: 4:00PM EST

3.4100 +0.01 (0.29%)
After hours: 5:18PM EST

Stock chart is not supported by your current browser
Previous close3.4900
Open3.4900
Bid3.4000 x 1300
Ask3.4800 x 1400
Day's range3.3850 - 3.5200
52-week range2.1700 - 53.1000
Volume177,409
Avg. volume674,658
Market cap88.758M
Beta (5Y monthly)-1.16
PE ratio (TTM)N/A
EPS (TTM)-1.3870
Earnings date06 Nov 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.96
  • Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • Do Insiders Own Shares In InflaRx N.V. (NASDAQ:IFRX)?
    Simply Wall St.

    Do Insiders Own Shares In InflaRx N.V. (NASDAQ:IFRX)?

    If you want to know who really controls InflaRx N.V. (NASDAQ:IFRX), then you'll have to look at the makeup of its...

  • InflaRx Enters Oversold Territory
    Zacks

    InflaRx Enters Oversold Territory

    InflaRx has been on a bit of a cold streak lately.

  • InflaRx N.V. (IFRX) Reports Q1 Loss, Lags Revenue Estimates
    Zacks

    InflaRx N.V. (IFRX) Reports Q1 Loss, Lags Revenue Estimates

    InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 30.65% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • InflaRx (IFRX) Catches Eye: Stock Jumps 7.5%
    Zacks

    InflaRx (IFRX) Catches Eye: Stock Jumps 7.5%

    InflaRx (IFRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • InflaRx (NASDAQ:IFRX) Shareholders Booked A 63% Gain In The Last Year
    Simply Wall St.

    InflaRx (NASDAQ:IFRX) Shareholders Booked A 63% Gain In The Last Year

    These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick the right individual stocks, you could make moreRead More...

  • Globe Newswire

    InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum

    * Third autoimmune disease being evaluated with IFX-1 * Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful ulcersJENA, Germany, Feb. 27, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the approval of a Clinical Trial Application by Health Canada for a phase IIa clinical trial evaluating the Company’s lead product candidate, IFX-1, in Pyoderma Gangraenosum. This is the third autoimmune disease for which InflaRx is developing IFX-1.Pyoderma Gangraenosum (PG) is a rare and debilitating neutrophilic-driven, autoinflammatory disease, characterized by an acute, destructive ulcerating process of the skin, primarily occurring on the legs. The exact prevalence of PG is not yet known, but it is estimated that up to 50,000 patients in the US and Europe are affected by this disease.“Pyoderma Gangraenosum is a debilitating disease with limited treatment options and frequent recurrence of open leg ulcers,” said Othmar Zenker, M.D., Chief Medical Officer of InflaRx. “Given the role that neutrophils appear to play in this disease, we believe that IFX-1, which targets a key inflammatory-causing protein that binds to these cells, has the potential to play a role in combatting PG. We are pleased to have received approval to initiate a clinical trial, and our team is excited to evaluate the safety and efficacy of IFX-1 in this indication.”The phase IIa study is an open label study to evaluate IFX-1 in approximately 12 patients with moderate to severe PG. The study is anticipated to initially be conducted at 3 sites in Canada. IFX-1 will be administered over a 12-week period. The main objectives of the study are to evaluate the safety of IFX-1, as well as to achieve clinical proof of concept based on relevant efficacy parameters. Trial enrolment is planned to start in the second quarter of 2019.About IFX-1: IFX-1 is a first-in-class monoclonal anti-complement factor C5a antibody which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. IFX-1 is believed to be the first monoclonal anti-C5a antibody introduced into clinical development and has, to date, successfully completed three clinical phase II studies. More than 150 people have been treated with IFX-1 in these completed clinical trials, and the antibody has been shown to be well tolerated. IFX-1 is currently being developed for various inflammatory indications, including Hidradenitis Suppurativa and ANCA-associated vasculitis.About InflaRx N.V.: InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. For further information please visit www.inflarx.com.Contacts: Investor Relations InflaRx N.V. Jordan Silverstein Head of Corporate Development and Strategy jordan.silverstein[at]inflarx.de +1 917 837 1709Media Relations MC Services AG Katja Arnold, Laurie Doyle, Andreas Jungfer Email: inflarx[at]mc-services.eu Tel: +49 89 210 2280FORWARD LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

  • Globe Newswire

    Richard Brudnick to Join InflaRx Board of Directors

    JENA, Germany, Feb. 14, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that Mr. Richard Brudnick has been appointed as interim Non-Executive Director to the Board of Directors of InflaRx N.V. Mr. Brudnick has substantial experience in the biotechnology and healthcare industry and is currently serving as Chief Business Officer and Head of Strategy for Codiak BioSciences. He brings extensive commercial and business development expertise to InflaRx as the Company’s pipeline progresses towards commercialization. The confirmed appointment of Mr. Brudnick as a Non-Executive Director of the Board is subject to the approval at the Annual General Meeting of Shareholders in May 2019. Prior to such time, Mr. Brudnick will attend board meetings as a non-voting observer. “Our team is delighted to have Mr. Richard Brudnick join our Board of Directors,” said Prof. Niels Riedemann, MD, PhD, Chief Executive Officer and founder of InflaRx. “Mr. Brudnick brings with him a unique business experience as InflaRx is defining its go-to-market strategy. His in-depth knowledge of the industry and his exceptional network will be invaluable assets to InflaRx going forward.”“I am excited to join the InflaRx Board of Directors to participate in accelerating the Company’s continued growth,” stated Mr. Brudnick. “I am impressed with the Company’s achievements to date, and its increasing visibility in the market. I look forward to contributing to the Company’s success as its pipeline expands across multiple indications.”Richard Brudnick currently serves as Chief Business Officer and Head of Strategy for Codiak BioSciences, a leader in the field of exosome therapeutics. Prior to joining Codiak, Mr. Brudnick was Executive Vice President of Business Development and Alliance Management at Bioverativ, Inc., a company he helped found in 2016. Prior to Bioverativ’s acquisition by Sanofi in March 2018, Mr. Brudnick led business development efforts to build a significant pipeline in rare blood disorders, including an acquisition, a multi-product collaboration and additional scientific collaborations and licenses. Mr. Brudnick joined Bioverativ at its spin-off from Biogen where, over the course of nearly 15 years, he initiated, led and completed transactions that now include several of the company’s marketed products and late-stage pipeline, including Tecfidera, Spinraza and its biosimilars joint venture with Samsung. Mr. Brudnick also was CEO of a regional pharmaceutical distribution business, which he sold to a strategic buyer; co-founded two companies; and was a strategy consultant at Bain & Company.About InflaRx N.V.: InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, MI and New York, NY, USA. For further information please visit www.inflarx.com.Contacts: Investor Relations InflaRx N.V. Jordan Silverstein Head of Corporate Development and Strategy Jordan.silverstein[at]inflarx.de +1-917-837-1709Media Relations MC Services AG Katja Arnold, Laurie Doyle, Andreas Jungfer inflarx[at]mc-services.eu +49-89-210 2280FORWARD LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’ periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

  • Globe Newswire

    InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa

    * Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatment * Baseline characteristics from ongoing phase IIb SHINE trial in line with expectations; on track for topline results Q2 2019 JENA, Germany and NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced that new clinical data with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with moderate to severe Hidradenitis Suppurativa (HS) are to be presented this week at the 8th Conference of the European Hidradenitis Suppurativa Foundation in Wrocław, Poland. HS is a painful and debilitating chronic inflammatory skin disease with limited treatment options. Retrospective long-term data from phase IIa trial: As previously reported, an open-label phase IIa clinical trial in 12 patients with severe HS showed a response of 75% according to HS Clinical Response (HiSCR) criteria at the end of an 8-week treatment period and 83% at the end of a 12-week treatment-free follow-up period. The results to be reported on February 8th are from an additional retrospective evaluation of the long-term effect of IFX-1post treatment.  Ten  of the 12 patients were available for this analysis. The median observation period after the last IFX-1 treatment was 226 days (range 119 to 324 days). The long-term efficacy was assessed by the abscess and inflammatory nodule count (AN count), number of draining fistulas, HiSCR assessment, and the occurrence of flares. Flares were defined as deterioration of HS requiring antibiotic therapy. Two flares occurred during the treatment period, and two flares occurred during the scheduled follow-up period. In the long-term follow-up, there were 26 flares, ranging from two to four per patient. The median time to the first flare after stopping IFX-1 treatment was 209 days (range 54 to 318 days), while off of medication, 50% of patients had no flares to day 203. Further analyses of AN count, number of draining fistulas, and HiSCR supported the assumption of the long-lasting effect of IFX-1 after stopping treatment. Prof. Dr. med. Evangelos J. Giamarellos-Bourboulis, ATTIKON University Hospital in Athens, Greece, the principal investigator of this trial, commenting on the IFX-1 data, said: “It is gratifying to see that sustained remission was observed in most patients treated with IFX-1. It is notable that after only 8 weeks of treatment, the median time to the first flare was almost seven months. With limited options for Hidradenitis Suppurativa, there is a major need to find more effective therapies that can provide relief over an extended period of time. I look forward to seeing the results from the ongoing randomized study with IFX-1 in this indication, which should give us additional insight into the efficacy and safety of this novel treatment for this debilitating condition.” Baseline characteristics from ongoing phase IIb trial: Dr. Giamarellos-Bourboulis is also to present the blinded baseline characteristics from an ongoing prospective, randomized, multicenter, double-blind, placebo-controlled phase IIb trial evaluating IFX-1 in patients with moderate to severe HS. The primary objective of the trial is to evaluate a dose response signal of IFX-1 with HiSCR at week 16. InflaRx announced completion of enrollment in November 2018. A blinded snapshot of the clinical database was performed, and available data from 179 patients at baseline are being reported. 56% of the patients are female, and 44% are male, with a mean age of 37.1 years old, and mean body weight of 92.2 kg. The median duration of HS was 8 years (range 1 to 39 years); while 59% and 41% of patients were classified as Hurley Stage 2 or 3, respectively. The median inflammatory nodule count at baseline was 9 (range 3 to 58). These baseline demographical data and characteristics are in-line with the overall moderate to severe HS population, and similar to that of other clinical studies in this field. Topline results from the phase IIb study are expected during the second quarter of 2019. Othmar Zenker, M.D., Chief Medical Officer of InflaRx, said: “We are pleased that the phase IIb study in Hidradenitis Suppurativa is advancing according to plan. The goal with this trial is to determine the optimal dose regimen, as well as assess both the long‑term efficacy and safety of IFX-1 in patients with this disease. We look forward to advancing to the next stages of development in this important indication.” About Hidradenitis Suppurativa (HS) HS is a chronic debilitating systemic skin disease which results in painful inflammation of the hair follicles, typically in the armpit, groin and genitalia regions. HS patients suffer primarily from pain driven by inflamed nodules and abscess formation and significant discomfort resulting from the constant formation of pus, particularly in the areas described above, leading to social isolation. HS is typically present after adolescence and often develops into a life-long debilitating chronic disease. In the United States, up to 200,000 patients are affected annually with moderate to severe disease (Hurley stages 2 to 3), with a current increase in recognition and diagnoses being expected and discussed amongst key opinion leaders. In Europe, the number of affected patients is considered to be higher with a trend of more cases of HS in countries with overall warmer climates. The standard of care for HS patients includes antibiotic treatment, which often only provides temporary symptomatic relief. In some cases, patients also undergo surgery. The only approved biological drug in this indication for moderate to severe HS patients is an anti-TNF-alpha monoclonal antibody. About IFX-1: IFX-1 is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. IFX-1 is believed to be the first monoclonal anti-C5a antibody introduced into clinical development and has, to date, successfully completed three clinical phase II studies. More than 150 people have been treated with IFX-1 in these completed clinical trials, and the antibody has been shown to be well tolerated. IFX-1 is currently being developed for various inflammatory indications, including Hidradenitis Suppurativa and ANCA-associated vasculitis. About InflaRx N.V.: InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, MI and New York, NY. Contacts: Investor Relations InflaRx N.V. Jordan Silverstein Head of Corporate Development and Strategy Jordan.silverstein[at]inflarx.de +1-917-837-1709 Media Relations MC Services AG Katja Arnold, Laurie Doyle, Andreas Jungfer inflarx[at]mc-services.eu +49-89-210 2280 FORWARD LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’ periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more